Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer’s disease by inhibition of glial activation, cholinesterase, and oxidative stress - 21/10/16
, Farnaz Nikbakht b, Mehrdad Roghani c, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Alzheimer’s disease (AD) is a multifactorial disorder with devastating outcomes and few mostly palliative available therapeutic strategies. Pelargonidin (Pel), an anthocyanin compound, is an estrogen receptor agonist with lower side effects versus estrogen. This study examined neuroprotective effect of Pel on intrahippocampal amyloid β25-35 (Aβ) rat model of AD. Rats were divided into groups of sham, Aβ, and Pel-pretreated Aβ (10mg/kg; p.o.). Animals underwent Morris water maze (MWM) test in addition to measurement of hippocampal oxidative stress, acetylcholinesterase (AChE) activity, glial fibrillary acidic protein (GFAP) and inducible nitric oxide synthase (iNOS). Pel pretreatment of Aβ group significantly improved escape latency and distance swum in MWM versus Aβ group and attenuated hippocampal malondialdehyde (MDA) and increased catalase activity with no significant change of nitrite. Meanwhile, Pel improved hippocampal AChE activity and lowered GFAP level with no significant change of iNOS. Our results suggest that Pel could improve Aβ25-35-induced memory deficit through mitigation of oxidative stress, cholinergic dysfunction, and astrocyte reaction.
Le texte complet de cet article est disponible en PDF.Keywords : Pelargonidin, β amyloid, Oxidative stress, Glial fibrillary acidic protein, Acetylcholinesterase, Inducible nitric oxide synthase
Plan
Vol 83
P. 85-91 - octobre 2016 Retour au numéro
Article précédent
- Nanomedicine-based combination of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma
- Lei Liu, Xiao-Jun Qi, Zhao-Kun Zhong, En-Ning Zhang
- Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis
- Sanaa Eissa, Marwa Matboli, Miram M. Bekhet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?